• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.12% Nasdaq Up0.71%

    Puma Biotechnology, Inc. (PBYI)

    222.10 Down 6.35(2.78%) Apr 24, 4:01PM EDT
    |After Hours : 224.72 Up 2.62 (1.18%) Apr 24, 4:10PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Puma Biotechnology, Inc.
    10880 Wilshire Boulevard
    Suite 2150
    Los Angeles, CA 90024
    United States - Map
    Phone: 424-248-6500
    Fax: 424-248-6501
    Website: http://www.pumabiotechnology.com

    Index Membership:N/A
    Full Time Employees:120

    Business Summary 

    Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Puma Biotechnology, Inc.

    Corporate Governance 
    Puma Biotechnology, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 2; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Alan H. Auerbach , 45
    Founder, Chairman of The Board, Chief Exec. Officer, Pres, Sec. and Member of Stock Option Committee
    Mr. Charles R. Eyler , 67
    Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. & Admin. and Treasurer
    Dr. Richard P. Bryce MBChB, MRCGP, MFPM, 57
    Sr. VP of Clinical R&D
    Mr. Erin Jones ,
    VP of Global Regulatory Affairs, Medical Writing & Pharmacology/Toxicology
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders